ESC2025 Premium Access

Residual risk of hospitalization & all-cause mortality among patients with heart failure with reduced ejection fraction without worsening heart failure who received guideline-directed medical therapy

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Congress Presentation

About the speaker

Doctor Andra Stevenson

Chatham (United States of America)
2 presentations
0 follower

6 more presentations in this session

Dose titration among patients receiving vericiguat in real-world clinical practice and association with clinical outcomes and health care resource use

Speaker: Doctor A. Ambrosy (San Francisco, US)

Thumbnail

Guideline-directed medication therapy use among patients with HFrEF receiving vericiguat: comparing findings from a real-world study to clinical trials

Speaker: Doctor A. Ambrosy (San Francisco, US)

Thumbnail

Impact of comprehensive heart failure management initiated during hospitalization on clinical outcomes in patients with decompensated heart failure with reduced ejection fraction

Speaker: Associate Professor R. Christodorescu (Timisoara, RO)

Thumbnail

Cardiac cGMP augmentation and hemodynamic improvement in heart failure with reduced ejection fraction: evidence from sacubitril/valsartan and vericiguat treatment

Speaker: Doctor T. Inoue (Sendai, JP)

Thumbnail

Association of myocardial damage assessed by 99mTc-MIBI scintigraphy with exercise capacity and clinical outcomes in patients with heart failure

Speaker: Doctor H. Mima (Suita, JP)

Thumbnail

Access the full session

Approaches to declining ejection fraction

Speakers: Doctor A. Stevenson, Doctor A. Ambrosy, Doctor A. Ambrosy, Associate Professor R. Christodorescu, Doctor T. Inoue...
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations